share_log

Advaxis (NASDAQ:ADXS) Coverage Initiated at StockNews.com

Advaxis (NASDAQ:ADXS) Coverage Initiated at StockNews.com

AdvAxis(纳斯达克股票代码：ADXS)在StockNews.com上开始报道
kopsource ·  2022/09/20 01:31

StockNews.com assumed coverage on shares of Advaxis (NASDAQ:ADXS – Get Rating) in a report published on Friday. The firm issued a sell rating on the stock.

斯托克新闻网在周五发布的一份报告中对Advaxis(纳斯达克：ADXS-GET Rating)的股票进行了报道。该公司对该股发布了卖出评级。

Advaxis Price Performance

Advaxis性价比

Shares of ADXS stock opened at $2.86 on Friday. The company has a market cap of $5.19 million, a P/E ratio of -0.32 and a beta of 2.20. Advaxis has a twelve month low of $1.02 and a twelve month high of $44.80.

上周五，ADXS股票开盘报2.86美元。该公司市值为519万美元，市盈率为-0.32，贝塔系数为2.20。Advaxis的12个月低点为1.02美元，12个月高位为44.80美元。

Get
到达
Advaxis
前进轴
alerts:
警报：

Advaxis Company Profile

Advaxis公司简介

(Get Rating)

(获取评级)

Advaxis, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer.
Advaxis，Inc.是一家临床阶段的生物技术公司，专注于在美国发现、开发和商业化专有的单核细胞增生性李斯特菌(LM)技术抗原递送产品。该公司正在开发ADXS-PSA，这是用于治疗转移性前列腺癌的第二阶段临床试验；ADXS-503，用于治疗非小细胞肺癌；以及ADXS-504，用于治疗前列腺癌。

See Also

另请参阅

  • Get a free copy of the StockNews.com research report on Advaxis (ADXS)
  • Lucid is Looking Like a Clear EV Winner
  • Still Lovin' It: Investors Keep Visiting McDonald's
  • Did FedEx Just Deliver A Buying Opportunity?
  • Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
  • Upwork Shares Stumble into Bargain Territory
  • 免费获取StockNews.com关于Advaxis的研究报告(ADXS)
  • Lucid看起来像是电动汽车的赢家
  • 仍然爱着它：投资者继续光顾麦当劳
  • 联邦快递刚刚提供了一个买入机会吗？
  • 自动区重新进入拉力赛模式，新高在望
  • Upwork股价跌入便宜货领域

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.

接受Advaxis Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Advaxis和相关公司的最新新闻和分析师评级的每日简要摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发